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Chelator free gallium-68 radiolabelling of
silica coated iron oxide nanorods via surface
interactions†
Benjamin P. Burke,a,b Neazar Baghdadi,a Alicja E. Kownacka,a Shubhanchi Nigam,a,b
Gonçalo S. Clemente,b,c Mustafa M. Al-Yassiry,a Juozas Domarkas,a,b Mark Lorch,a
Martin Pickles,d Peter Gibbs,d Raphaël Tripier,e Christopher Cawthorneb,c and
Stephen J. Archibald*a,b
The commercial availability of combined magnetic resonance imaging (MRI)/positron emission tomo-
graphy (PET) scanners for clinical use has increased demand for easily prepared agents which oﬀer signal
or contrast in both modalities. Herein we describe a new class of silica coated iron–oxide nanorods (NRs)
coated with polyethylene glycol (PEG) and/or a tetraazamacrocyclic chelator (DO3A). Studies of the
coated NRs validate their composition and conﬁrm their properties as in vivo T2 MRI contrast agents.
Radiolabelling studies with the positron emitting radioisotope gallium-68 (t1/2 = 68 min) demonstrate
that, in the presence of the silica coating, the macrocyclic chelator was not required for preparation of
highly stable radiometal-NR constructs. In vivo PET-CT and MR imaging studies show the expected high
liver uptake of gallium-68 radiolabelled nanorods with no signiﬁcant release of gallium-68 metal ions,
validating our innovation to provide a novel simple method for labelling of iron oxide NRs with a radio-
metal in the absence of a chelating unit that can be used for high sensitivity liver imaging.
1. Introduction
Medical imaging can be defined as the non-invasive visualisa-
tion of the intact human body for clinical analysis. Positron
Emission Tomography (PET) is a nuclear medicine technique
based on the detection of positron emitting radionuclides to
give a high sensitivity functional image.1–3 However, as a
molecular imaging technique, it does not provide anatomical
information and is, therefore, often combined with other tech-
niques, such as computed tomography (CT) or magnetic reso-
nance imaging (MRI). Although the combination of PET with
CT is most prevalent in the clinic, recent developments in
detector design have led to the creation of combined PET/MR
scanners that oﬀer advantages over PET/CT, such as increased
soft tissue contrast, lower radiation dose and the potential
application of MRI contrast agents.4,5 The introduction of
clinical PET/MRI scanners increases the demand for multi-
modal contrast agents, achieved either by using a cocktail of
known imaging agents or by developing new dual modality
contrast agents in which both components are linked into one
construct.6–9
Super-paramagnetic iron oxide nanoparticles (SPIONs) are
used in MRI to reduce the time taken for proton nuclei to
transfer their spin to neighbouring proton nuclei, resulting in
a loss of transverse magnetisation (T2 relaxation), causing a
relative darkening in regions of SPION accumulation.10,11
Iron–oxide based nanospheres have been the most commonly
used T2 contrast agents clinically,
12–14 largely because of
their low toxicity and the potential for facile modification of
the surface.15–17 Iron–oxide based nanorods (NRs) are less
common but may oﬀer advantages, such as improved
MRI contrast18–20 and improved properties as drug delivery
vehicles.21
68Ga (t1/2 = 68 min) is an attractive radioisotope for PET due
to high proportion of positron decay (89%) and its availability
from a generator based system as a decay product of a parent
isotope with a long half-life (68Ge, t1/2 = 271 days), eliminating
the need for an onsite cyclotron.22,23 In aqueous solution and
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at physiological pH, 68Ga is exclusively in the oxidation state
+3, thus most synthetic procedures are carried out in the pres-
ence of weakly coordinating ligands such as citrate, acetate or
oxalate at low pH in order to avoid the formation of insoluble
Ga(OH)3 and soluble Ga(OH)4
−, both of which dramatically
slow the kinetics of complex formation.24,25 Gallium(III) gener-
ally forms six coordinate complexes and is classified as a
hard Lewis acid, therefore, it binds to borderline and hard
Lewis base donor atoms such as nitrogen and oxygen,
found in routinely used chelators for biomedical imaging.26,27
Incorporation of 68Ga into a targeting vector is generally
achieved by the use of bifunctional chelating agents (BCAs),
molecules containing a chelating moiety responsible for
trapping 68Ga in a stable in vivo form, functionalised with
a reactive group allowing its conjugation to a bioactive mole-
cule, protein or peptide.28,29 1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) is the most widely employed
BCA due to the relative ease of its synthesis (due to its chemi-
cal symmetry) and the ability to complex, with adequate stabi-
lity, various metal ions relevant for a range of biomedical
applications.3,22,30,31
Herein we describe the development of silica coated iron
oxide NRs radiolabelled with gallium-68 for PET/MR multi-
modal imaging in which the inclusion of a bifunctional chelat-
ing agent (such as DOTA) is not required for stable gallium(III)
complexation in vivo.
2 Results & discussion
2.1. Synthesis and surface characterisation
Iron–oxide nanorods, coated with various ratios of a siloxane
terminated tetraazamacrocycle (siloxane-DO3A) and a siloxane
polyethylene glycol (PEG) derivative, were synthesised using a
modified method, similar to that previously reported by our
group.32 Briefly, uncoated iron oxide nanorods and the
selected ratio of functionalised siloxanes were stirred in a
basic 60% ethanol/water solution, as shown in Scheme 1. The
preparation includes a rigorous washing procedure followed by
resuspension of coated NRs in water and removal of macro
aggregates by filtration through a 0.45 μm filter. Macrocycle
coated nanoparticles were subsequently subjected to trifluoro-
acetic acid (TFA) hydrolysis to unmask the protected acetate
arms to give nanoparticles coated using 100% macrocycle (1)
and 50% macrocycle, 50% PEG (2). The 100% PEG coated NRs
(3) do not require a hydrolysis step.
Transmission electron microscopy (TEM) analysis was
carried out on the final constructs (1–3) to ensure that syn-
thetic coating protocols do not aﬀect the core iron–oxide struc-
ture, see Fig. 1. All constructs were found to have a similar size
distribution, with rods of length 80–130 nm. Fourier transform
infra-red (FTIR) spectroscopy was carried out to validate the
presence of the surface coating, see Fig. 2. All coating types
had the expected stretches of Fe–O, Si–O–C and Si–O–Fe
between 600 and 1000 cm−1.33 Surface coatings can be diﬀer-
entiated due to the independent peak characteristics of each
type. In case of 1, characteristic macrocycle-derived C–N
stretches can be assigned at ca. 1200 cm−1. In case of 3, C–O–C
linkage, characteristic to PEG, can be assigned at 1117 cm−1.
2 was designed to contain a mixture of coating component
and was produced using a 1 : 1 ratio of the two coating com-
ponents, with the FTIR showing a broad peak in the region
overlapping both regions. The chemical composition of
surface coating is corroborated by combustion analysis of
coated NRs nitrogen content (0.79, 0.29 and 0.00% for 1, 2 and
3, respectively) as the only inclusion of nitrogen is from the
Scheme 1 Synthesis of silica coated iron oxide nanorods 1–3.
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tetraazamacrocycle coating, decreasing for 2 relative to 1 as
expected, see Fig. S1.†
2.2. Nanorod construct analysis
The surface charge of nanoparticles gives an indication of
their aqueous suspension stability, an essential requirement
for translation to in vivo studies. A large negative or positive
value would suggest an increased electrostatic repulsion
between individual nanoparticles, decreasing the tendency for
aggregation.34–36 The zeta potential of the constructs (1–3) was
measured at a constant concentration (7.5 mM Fe) at pH 7 in
PBS, see Fig. S2.† All constructs have an overall negative
charge between −10 and −20 mV. Analogous PEG methyl ether
terminating nanoparticles have a similar surface charge37 and
DOTA based systems have deprotonated carboxylic acid groups
at pH 7.38,39 All constructs have a relatively similar zeta poten-
tial, with 2 having the highest negative potential at −17.9 mV.
The high negative surface charge of all constructs translates to
high stability in aqueous solution, with no visible precipitation
observed for any of the samples after 2 months.
The size of nanoparticles is an important characteristic gov-
erning their in vivo biodistribution pathways and, therefore,
determining their potential for application as MRI contrast
agents. Very small (<5 nm) nanoparticles are generally elimi-
nated via the renal system and large (>200 nm) nanoparticles
are excreted via the spleen and liver. Either of these elimin-
ation pathways results in short blood circulation times.10,40,41
Samples of all three constructs were suspended in water (at a
concentration of 0.1 mM Fe) and their hydrodynamic size was
measured by nanoparticle tracking analysis (NTA) in which
mean and modal sizes were determined, see Fig. S3.† The con-
structs had mean sizes in the range of 99–155 nm, with an
increase in size correlating with the addition of macrocycle to
the surface coating, all are an acceptable size for in vivo appli-
cations. There are challenges with NTA analysis and the use of
rods rather than spheres: (a) how do these numbers relate to
the diﬀerent nanorod axes?; and (b) are the in vivo excretion
pathways of the nanorods diﬀerent to that of the nanospheres
and, if so, what is the eﬀect of length?
Prior to radiolabelling and in vivo studies, the magnetic be-
haviour of the NR constructs was investigated in vitro at 3 T, a
magnetic field strength correlating to common clinical MRI
scanners. The r1 and r2 relaxation rates were calculated for all
three constructs (1–3), see Fig. 3 and 4. All constructs are rela-
tively weak T1 contrast agents. As T2 contrast agents, all con-
structs showed fast relaxivity with improvement correlated to
the increasing PEG content of the NR coating.
The large variability in both r1 and r2 values, as a function
of chemical composition of surface coating, could be
explained by a combination of factors, such as variation of
hydrodynamic size, hydrophilicity and permeability of the
diﬀerent coatings to water molecules.42 The increase in hydro-
dynamic size inversely correlates with both r1 and r2 values.
Although superparamagnetic contrast agents generate a long-
range magnetic field for the spin-spin relaxation (T2) process,
this eﬀect decreases as distance increases. Similarly, as the
mechanism for transverse (T1) relaxation is proximity based,
an increase in coating thickness leads to a decrease in r1
Fig. 1 TEM images of iron oxide nanorods 1–3.
Fig. 2 FTIR spectra of nanorods 1–3.
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values.43 The hydrophilicity and permeability of the surface
coating also has an eﬀect on relaxivity rates,44 although more
relevant for T1 relaxation, varying the ease of water molecule
access to the iron surface. The more easily that water mole-
cules can transfer into close proximity with the iron surface,
and exchange rapidly, the faster the relaxivity rates.
2.3. Gallium-68 radiolabelling and stability
In aqueous solutions, gallium is almost exclusively found in
the oxidation state +3, and is highly influenced by pH, with
the optimal coordination conditions situated between pH 3
and 5, since a more acidic environment may inhibit the
complex formation due to protonation of donor atoms, and a
neutral or basic environment causes unreactive hydroxides to
form. The constructs described in this study were prepared
and radiolabelled with 68GaCl3 following a standard pro-
cedure.32 Briefly, to a dried aliquot of 68GaCl3 was added a
sample of NRs in 0.2 M sodium acetate solution and the
reaction mixture was heated to 90 °C for 15 minutes, whilst
monitoring by radio-thin layer chromatography (radio-TLC). In
accordance with our previous results, the macrocyclic chelator
was not required for the radiochemical incorporation of
gallium-68 and quantitative radiolabelling was achieved in a
15 minute reaction time.32 In order to simulate conditions of
possible gallium(III) ion release in vivo, two assays were per-
formed, see Fig. 5. Firstly, the radiolabelled constructs were
incubated in human serum. All three constructs (1–3) showed
high stability (>95%) after 3 hours at 37 °C, a reasonable time
point considering the short half-life of gallium-68 (68 min). As
gallium(III) has a similar atomic radius to iron(II), the primary
mechanism for gallium(III) bioprocessing in vivo is via iron ion
pathways, such as complexation with apo-trasnferrin in blood
plasma.45 In order to probe this property, the radiolabelled
constructs (1–3) were incubated with an excess of apo-trans-
ferrin (0.5 mg) at 37 °C. Again, after 3 hours >95% of gallium-68
remained attached to the constructs, with no significant diﬀer-
ence observed between diﬀerently coated NRs in either assay.
Fig. 4 T2 MRI relaxivity plots of 1–3 at a range of Fe concentrations
(0.1–1 mM) at 3 T to determine r2.
Fig. 3 T1 MRI relaxivity plots of 1–3 at a range of Fe concentrations
(0.1–1 mM) at 3 T to determine r1.
Fig. 5 Radiochemical stability of gallium-68 radiolabelled 1–3 in human serum (left) and apo-transferrin (right) over 3 hours, measured via
radio-TLC.
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Importantly, the 68Ga radiolabelling results indicate that a
bifunctional chelating agent is not required for rapid radio-
labelling or to stably attach the metal ion in vitro, as demon-
strated in chelator competition assays, with 3 showing
analogous labelling stability to 1 and 2. Experiments on com-
parable non-PEG silica coatings using triethoxy(ethyl)silane
(data not shown) yielded equivalent radiochemical results,
indicating that the eﬀect is not solely a property of the PEG
chains. Spectroscopic analysis of non-radioactive 69/71Ga
isotope analogues failed to provide data on the existence of
Ga–O–Si or Ga–O bonds as the peaks were masked by the
intense Fe–O–Si and Fe–O peaks. Due to the polymeric
nature of the surface coating and the high density, deter-
mined to be 37% w/w or 5.62 ligands per nm2 of iron oxide
for 3 (see Fig. S4†),46 we assume that the attachment of
gallium(III) to the core is unlikely. In order to assess the
hypothesis of the formation of Ga–O–Si bonds, we attempted
the 68Ga radiochemistry at a lower pH, which would cause
siloxy protonation and hence would not be able to react with
the gallium(III). Reactions performed at pH 2 with 3 using the
same temperature and reaction time yielded only 4.4% ± 0.9
(n = 3) RCY. Also, by modifying the pH of the same reactions
back up to 5 and heating again for 15 minutes, the RCY
increased to 96.7% ± 1.5 (n = 3), supporting this hypothesis.
2.4. In vivo imaging biodistribution and stability
All three radiolabelled NRs demonstrate comparable in vitro
stability. The most interesting construct is 3 due to its lack of a
chelator moiety. Thus, PET-CT and MR imaging studies were
carried out in mice using gallium-68 labelled 3 to assess the
co-localisation of PET and MRI signals and evaluate the in vivo
stability of the construct.
Iron oxide nanoparticles of a similar size to ones used in
this study are quickly taken up by the reticuloendothelial
system (RES) and accumulate in the liver and spleen.12,37,47
PET scanning revealed that the 68Ga-3 construct rapidly
(<5 min) accumulated in the liver (Fig. 6). Some limited uptake
in the lung was noted in some scans; this has been observed
previously with iron oxide nanoparticles and has been attribu-
ted to possible embolisation caused by post-injection aggrega-
tion.48,49 After the PET-CT study the mouse was transferred to
the MR scanner and both T1 and T2 MR images were acquired
(see Fig. 6 and S6†). As expected the liver T1 signal was not
significantly aﬀected by the 68Ga-3 construct. Whereas T2
weighted images revealed hypointense liver signal intensity,
indicating localisation of the iron oxide NRs in the liver.
As a comparison, 68Ga3+ was administered as gallium(III)
citrate and its biodistributon assessed in order to observe the
biodistribution that may occur if the 68Ga were released from
Fig. 6 In vivo mouse images of (a) 10 MBq/50 μg Fe of 68Ga-3, fused PET-CT coronal slice image showing areas of main organ uptake at
80–90 minutes post-injection, (b) 10 MBq/50 μg Fe 68Ga-3, T2 weighted MR image at 90 minutes post-injection, (c) control mouse without nano-
particle administration, T2 weighted MR image at 90 minutes post-injection and (d) time-activity-curve for major organs from PET image after
administration of 10 MBq/50 μg Fe of 68Ga-3.
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the nanorod in vivo. PET scans show that the ‘free’ 68Ga3+ is
distributed more widely throughout multiple organs and is
cleared much more slowly from the blood pool, see Fig. S5.† A
significantly lower amount of radioactivity is noted in the liver,
which is expected due to 68Ga coordination to transferrin.
The presence of 68Ga on the nanoparticle was also confirmed
by ex vivo analysis, see Fig. S7.† After sacrifice (90 min post-
injection), the liver was harvested and processed to separate the
nanoparticles from the cell pellet, after which radio-TLC was
used to determine if the radioactivity was still attached to the
nanoparticle. As a comparison, the same experiment was
carried out after independent administration of 68Ga-citrate and
68Ga-transferrin. It can be seen that after administration of
68Ga3+ or 68Ga-transferrin, the majority of the radioactivity is
attached to transferrin. When 68Ga-3 is administered, >90% of
the radioactivity is still attached to the nanorods even after ana-
lysis 90 min post-injection, which is a relatively late in vivo time
point for gallium-68 imaging given its short half-life.
Debate is ongoing as to the best design parameters and
applications for combined PET/MR imaging agents.50 Iron–
oxide nanoparticles of this size localise in the liver via phago-
cytosis into the Kupﬀer cells and malignant liver legions often
lack normal Kupﬀer cells and remain “bright” in an MRI scan
upon SPION administration.51,52 However, the lower MRI sen-
sitivity means that diﬀerentiation between regions with and
without SPION may be challenging and may limit widespread
clinical utility. Clinical utility could be increased by using PET
radioisotope labelled SPIONs such as those developed in this
study due to the increased sensitivity of PET and subsequent
clarity of low uptake regions.
3 Conclusion
In this study, we have demonstrated that the positron emitting
radioisotope 68Ga can be used to radiolabel silica coated iron–
oxide nanorods via surface interactions in the absence of a
bifunctional chelating agent. Studies of 68Ga-3 (NRs coated
with 100% PEG) confirm that the construct is stable in vivo
and demonstrate its applicability as a PET/MR multimodal
imaging agent. This is particularly interesting, because coated
NRs can be easily obtained in one step from commercial
materials, removing challenging and complex organic syn-
thesis steps. Thus, this study establishes a novel straight-
forward method for the preparation of PET/MR multimodal
imaging agents which have the potential to combine the high
sensitivity of PET with MR contrast for malignant liver lesion
imaging and also oﬀer the potential for facile surface labelling
methods that can be applied to currently licensed iron oxide
MRI contrast agents for clinical use. This would facilitate more
rapid progress through patient trials to regulatory approval.
4 Experimental
4.1. Materials and methods
Tri-tert-butyl-2,2′,2″-(10-(2-hydroxy-3-(3-(triethoxysilyl)propoxy)-
propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
(Siloxane-DO3A) and uncoated iron oxide nanorods were
synthesised following literature proceedures.32 2-Methoxy-
(polyethyleneoxy) propyltrimethoxysilane (Siloxane-PEG,
MW 1120–1250) was purchased from Gelest Inc. (Germany). All
other chemicals were purchased from Sigma Aldrich, Acros or
Alfa Aesar. External rare earth magnet (N42, NdFeB, 30 × 30 ×
40 mm) was purchased from MagnetExpert Ltd. Transition
Emission Microscopy (TEM) was performed on air dried suit-
able diluted samples deposited on a carbon-coated copper
grid. Images were obtained using a Gatan US4000 digital
camera (Gatan UK, Abingdon, Oxford) mounted onto a JEOL
2010 transmission electron microscope (Jeol UK) running at
200 kV. FTIR spectra were collected using a Fourier transform
infra-red spectrometer manufactured by Perkin Elmer (model
Spectrum RXI). Nanoparticle tracking analysis (NTA) was
carried out with a LM10-HS microscope from NanoSight®
using a 75 mW laser at 532 nm (green). Zeta potential was
measured with Zeta Nanosizer (Malvern Instruments,
ZEN3600, UK) at 25 °C, the conversion of the electrophoretic
mobility (µ) into zeta potential (ζ) was performed using the
Smoluchowski equation. Elemental analysis for carbon, hydro-
gen and nitrogen was carried out using a CHN analyser
EA1108 (Carlo Erba). Inductively Coupled Optical Emission
Spectroscopy (ICP-OES) analysis was performed using a Perkin
Elmer Optima 5300 DV. All the samples were in solid state,
digested with aqua regia in glass sample vials on a hotplate.
Calibration standards were prepared at 1 and 10 ppm from
1000 ppm concentrates of iron and silicon which were pur-
chased from Romil UK. Gallium-68 was eluted from a 740 MBq
68Ge/68Ga generator (iThemba LABS/IDB Holland) and pre-
pared for synthesis following literature methods.32 Radio-TLC
analyses were carried out using either a 1480 Wizard 3″
Gamma Counter or Lablogic Scan-Ram, equipped with a NaI
detector at a speed of 10 mm min−1. Data were recorded using
Lablogic Laura (version 4.1.7.70) after developing silica plates
(TLC-SG, Merck KGaA) in aqueous 0.1 M citric acid to separate
68Ga-NRs (Rf = 0),
68Ga-transferrin (Rf = 0.5) and
68Ga3+ (Rf = 1).
4.2. Synthesis of coated iron–oxide nanorods
General procedure for coating nanorods with siloxanes: freshly
prepared nanorods were coated with siloxane-DO3A and
2-methoxy(polyethyleneoxy) propyltrimethoxysilane (Siloxane-
PEG) in diﬀerent ratios. In each reaction, bare NRs (0.3 g,
1.3 mmol) were suspended under nitrogen in 60% ethanol
(100 ml) by extensive sonication. Ammonium hydroxide
(20 ml, 35%) was added drop-wise and the solution was stirred
for 30 min. The designated ratio of siloxane-DO3A and silox-
ane-PEG (total 0.34 mmol) was dissolved in ethanol (10 ml)
and added over 10 min, the reaction was then stirred for
48 hours at room temperature. The solid precipitate formed
was attracted to the bottom of the flask using an external rare
earth magnet and the clear aqueous supernatant liquid was
decanted. The washing and decanting procedure was repeated
with 60% ethanol (2 × 100 ml), ethanol (2 × 100 ml), methanol
(2 × 100 ml) and diethyl ether (100 ml) and dried. The crude
sample was re-suspended in water (20 ml) filtered through a
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5 μm filter followed by a 0.45 μm filter (Merck®) and dried
under high vacuum to give coated NRs as a black/brown
powder. Nanorods functionalised with 100% siloxane-DO3A or
with 50% siloxane-DO3A were suspended in DCM (20 ml), TFA
(2 ml) was added and the reaction was shaken at room temp-
erature for 24 hours. The solid precipitate was attracted to the
bottom of the flask using an external rare earth magnet and
the clear aqueous supernatant liquid was decanted. The washing
and decanting procedure was repeated with ethanol (2 × 20 ml),
methanol (20 ml) and diethyl ether (100 ml) and dried. As pre-
viously, the crude sample was re-suspended in water (20 ml)
filtered through a 5 μm filter followed by a 0.45 μm filter
(Merck®) and dried under high vacuum to give coated NRs as a
black/brown powder. (1 = 124 mg, 2 = 154 mg, 3 = 97 mg).
4.3. MRI relaxivity studies
Relaxivity measurements were carried out on a clinical 3.0 T
Discovery MR750 General Electric scanner. Longitudinal (T1)
and transverse (T2) relaxation times were determined at a
range of iron concentrations: 1, 0.5, 0.25 and 0.125 mM in
water. A linear plot of concentration versus 1/relaxation time
gives r1 and r2 as the plot gradient.
4.4. PET/CT image acquisition and image analysis
CD1 nude female mice (Charles River, UK) were anaesthetised
with 1–2% Isoflurane, the tail vein was catheterised and they
were placed in the Minerve Small-Animal Imaging Cell (Minerve,
France) and transferred to the SuperArgus 2R preclinical PET/CT
scanner (Sedecal, Spain). At the start of the PET acquisition,
animals were injected with ∼10 MBq, 50 µg Fe of 68Ga-3 intra-
venously(IV) via the tail vein and a 90-minute whole-body
imaging sequence acquired (2 bed positions of 2 × 60 s, 4 × 120 s
and 7 × 300 s). CT images were acquired via 360 projections/
8 shots at a tube voltage of 45 kV and current of 140 µA. Respir-
ation and temperature were monitored throughout using the
SA Instruments 1025 T monitoring system (SA Instruments,
CA, USA). All procedures were approved by the University of
Hull Animal Welfare Ethical Review Body (AWERB) and carried
out in accordance with the Animals in Scientific Procedures
Act 1986 and the UKCCCR Guideline 201053 by approved proto-
cols following institutional guidelines (Home Oﬃce Project
License number 60/4549 held by Dr. Cawthorne).
4.5. MR image acquisition
Magnetic resonance imaging was performed on a wide bore
vertical 11.7 T MR scanner (Bruker, Germany). With a 4 cm ver-
tical field of view with slide thickness’ of 1.0 mm and inter-
slice distances of 1.5 mm. T1 images were acquired using a
RARE inverse recovery sequence in which TE = 7.5 ms, TR =
3500 ms, flip angle = 180°, SW = 79 365.1 Hz. T2 images were
acquired using a T2 weighted FLASH sequence in which TE =
6.9 ms, TR = 350 ms, flip angle = 30°, SW = 50 505.1 Hz.
4.6. 68Ga-3 in vivo liver stability
68Ga-transferrin synthesis. Processed and dried 68GaCl3 was
added to apo-transferrin (0.5 mg) in water (200 μl) and incu-
bated at 37 °C for 30 minutes. Radio-TLC indicated the syn-
thesis of 68Ga-transferrin in >95% radiochemical purity.
Ex vivo liver processing. The liver was removed after sacri-
fice and ground in liquid nitrogen. The liver samples
(ca. 80 mg) were added to lysis buﬀer (New England Biolabs
(UK)) (10× w/w), sonicated for 10 minutes then centrifuged at
20 000 RPM for 10 minutes. The supernatant was separated
from the cell pellet. Radio-TLC was carried out on the super-
natant to determine gallium attachment.
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